NCT05346055

Brief Summary

The primary aim in this pilot project is to test the feasibility, acceptability and impact (decreased depressive symptoms) of a brief behavioral treatment for depression (Engage) combined with video social support (PRISM 2.0) among socially isolated/lonely case management clients who endorse depressive symptoms. Eligible participants will be offered the combination of Engage and Prism 2.0, called Engage-Prism. The investigators hypothesize that the intervention (Engage Therapy With Video Support) will be accepted by participants, improve depressive symptom, and be feasible to complete.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable depression

Timeline
Completed

Started May 2022

Shorter than P25 for not_applicable depression

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 20, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 26, 2022

Completed
16 days until next milestone

Study Start

First participant enrolled

May 12, 2022

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2022

Completed
9 months until next milestone

Results Posted

Study results publicly available

June 28, 2023

Completed
Last Updated

June 28, 2023

Status Verified

June 1, 2023

Enrollment Period

5 months

First QC Date

April 20, 2022

Results QC Date

June 5, 2023

Last Update Submit

June 5, 2023

Conditions

Keywords

Older Adults

Outcome Measures

Primary Outcomes (3)

  • Acceptability: Client Satisfaction Questionnaire (CSQ)

    The CSQ is a 3 - item questionnaire assessing client satisfaction with the treatment provided partway through the treatment (6 weeks). Scores range from 3 (least satisfied) to 12 (most satisfied).

    6 weeks (part-way through treatment)

  • Acceptability: Client Satisfaction Questionnaire (CSQ)

    The CSQ is a 3 - item questionnaire assessing client satisfaction with the treatment provided assessed at 3 weeks post treatment (at 12 weeks) Scores range from 3 (least satisfied) to 12 (most satisfied).

    12 weeks (post treatment)

  • Feasibility: Client Enrollment

    Feasibility will be measured as the number of clients who are referred to the program, meet eligibility and accept the intervention (versus refuse).

    Baseline

Secondary Outcomes (2)

  • Hamilton Depression Rating Scale

    Baseline, 9 weeks (end of treatment)

  • Hamilton Depression Rating Scale

    Baseline, 12 weeks (post treatment)

Study Arms (1)

Engage Prism 2.0

OTHER

Engage Prism is a 9-week program that integrates Engage- a form of behavioral talk therapy treating depression, and guided use of Prism technology- a software that aims to improve social support and interaction of older adults.

Behavioral: Engage Prism (2.0)

Interventions

Brief Behavioral Treatment for Depression (Engage) combined with tablet-based social support system (Prism 2.0)

Engage Prism 2.0

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age at least 60 years
  • English speaking
  • Currently enrolled in case management at in 2 included agencies
  • Major depression on the SCID
  • item Hamilton Depression Rating Scale (HAM-D) ≥ 19

You may not qualify if:

  • Psychotic depression by SCID-V, i.e. presence of delusions
  • High suicide risk, i.e. intent or plan to attempt suicide in the near future
  • Presence of any Axis I psychiatric disorder
  • Presence of substance abuse other than unipolar major depression
  • History of psychiatric disorders, hypomania, are excluded
  • Acute or severe medical illness, i.e. delirium, metastatic cancer, decompensated cardiac, liver, or kidney failure, major surgery, stroke, or myocardial infarction during the three months prior to entry; or drugs often causing depression, e.g. steroids, reserpine, alpha- methyl-dopa, tamoxiphen, vincristine
  • Current involvement in psychotherapy
  • Cognitive impairment (i.e. telephone administered MoCA \< 11)
  • Currently dwelling in non-community dwelling (e.g. prison, nursing home)
  • Hearing that would not allow participants to complete sessions with the RA/therapist
  • Vision impairment that would not allow the participant to use the study provided tablet
  • Inability to speak English
  • Aphasia interfering with communication
  • Literacy -assessed by reading a paragraph designed for those at 6th grade reading level

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Weill Cornell Medicine

New York, New York, 10065, United States

Location

MeSH Terms

Conditions

Depression

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Results Point of Contact

Title
Jo Anne Sirey
Organization
Weill Cornell Medical College

Study Officials

  • Natalie C Benda, PhD

    Weill Medical College of Cornell University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 20, 2022

First Posted

April 26, 2022

Study Start

May 12, 2022

Primary Completion

September 30, 2022

Study Completion

September 30, 2022

Last Updated

June 28, 2023

Results First Posted

June 28, 2023

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will share

Individual participant data that underlie the results in publications after de-identification, as well as study protocol, treatment manuals, statistical analysis plan and informed consent.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
After we publish the main results, we will make de-identified data available to other researchers under a data sharing agreement overseen by Weill Cornell Alacrity Center's executive committee.
Access Criteria
Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. All researchers requesting data solely for research purpose; secure the data; return or destroy it once analyses are completed; do not share it with other researchers.

Locations